SR-123781A Uses, Dosage, Side Effects and more
SR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).
| Attribute | Details |
|---|---|
| Trade Name | SR-123781A |
| Generic | SR-123781A |
| Type | |
| Formula | C127H201Na37O134S17 |
| Weight | Average: 5267.5 Monoisotopic: 5264.02818943 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in cardiovascular disorders, thrombosis, and venous thromboembolism.
How SR-123781A works
SR123781A is a synthetic hexadecasaccharide comprising an antithrombin (AT) binding domain, a thrombin binding domain, and a neutral methylated hexasaccharide sequence, was obtained from glucose through a convergent synthesis. SR123781A showed high affinity for human AT and was a potent catalyst of its inhibitory effect with regard to factor Xa and thrombin.
